ACADIA Pharma

ACADIA Pharmaceuticals, Inc. operates as a biopharmaceutical company. It focuses on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. The firm's products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

ACADIA Pharma reports strong Q4 earnings, eyes trofinetide launch

ACADIA Pharma showcased strong financial performance and strategic advancements in Q4 2022, with a focus on NUPLAZID and trofinetide for Rett syndrome treatment.
The company's commitment to innovation, positive payer discussions, and promising study results position it well for future success in the neuroscience space.
While facing challenges in managing expenses and post-approval logistics, ACADIA has opportunities to drive growth through market acceptance of trofinetide and expanding its patient base.
Overall, ACADIA's performance, strengths, and strategic outlook indicate a promising trajectory for the company, with key milestones ahead in 2023.

ACADIA Pharma reports solid Q1 performance and navigates strategic decisions

ACADIA Pharma's Q1 2023 performance reflects strong market acceptance of DAYBUE and steady growth in NUPLAZID market share.
The company's financial stability, progress in clinical programs, and strategic focus on real-world evidence studies position it well for future growth.
Challenges in decision-making, seasonality, and balancing profitability with pipeline expansion require strategic navigation.
Opportunities lie in exploring broader patient populations, leveraging real-world evidence, and making strategic decisions on the priority review voucher.

ACADIA Pharma reports robust Q2 sales, eyes global expansion

ACADIA Pharma's Q2 earnings call highlighted strong sales performance and milestone of cash flow neutrality
NUPLAZID and DAYBUE driving revenue growth, with plans for global expansion and new product approvals
Challenges include market dynamics in Parkinson's disease and addressing unmet needs in CNS disorders
Opportunities lie in late-stage programs, expanding market presence, and enhancing patient support initiatives

ACADIA Pharma reports robust Q3 earnings, eyes global expansion

ACADIA Pharma's Q3 2023 showcased strong financial performance, robust pipeline programs, and positive market reception for DAYBUE and NUPLAZID
Challenges with insurance coverage and study timelines were noted, but opportunities in global expansion and real-world evidence support growth potential
Overall, ACADIA Pharma's earnings call highlighted a solid foundation for continued growth and market leadership in neurological and psychiatric treatments

ACADIA Pharma posts record revenues, guides strong growth for 2024

ACADIA Pharma's Q4 earnings call highlighted strong commercial performance, robust pipeline, and solid financial position.
The company's focus on persistency rates, compliance, and guidance scenarios underpin their growth strategy for 2024.
Challenges include pipeline uncertainties and operational complexities, while opportunities lie in market expansion and optimization strategies.
Overall, ACADIA Pharma's emphasis on execution and strategic planning positions them for continued success in the pharmaceutical market.

ACADIA Pharma reports robust Q1 earnings, eyes global expansion

ACADIA Pharma's Q1 2024 showcased strong revenue growth and promising sales performance for key products.
The company's robust pipeline and focus on global expansion offer avenues for sustained growth.
Challenges in gross to net tracking and cost optimization require attention for future profitability.

ACADIA Pharma reports robust Q2 earnings, eyes market expansion opportunities

ACADIA Pharma's strong Q2 performance, driven by NUPLAZID and DAYBUE, showcases revenue growth and strategic marketing initiatives.
The company's financial stability, successful patient engagement strategies, and upcoming awareness campaigns position it well for future growth.
While facing challenges in sustaining sales momentum and market competition, ACADIA Pharma has opportunities to expand market reach and enhance therapy understanding.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ACADIA Pharmaceuticals, Inc. engages in the development and commercialization of medicines for central nervous system disorders. Its products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.

Acadia (ACAD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Acadia Pharmaceuticals (ACAD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report third quarter financial results on Wednesday, November 6, 2024, after the close of the U.S. financial markets. Acadia's management team will also host a conference call and webcast on November 6, 2024, at 4:30 p.m. Eastern Time to discuss financial results and operations. The conference call will be available on Acadia's website, Acadia.com under the investors section and will be archived.

Acadia Pharmaceuticals to Announce Third Quarter Financial Results on November 6, 2024

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Health Canada has granted marketing authorization of DAYBUE™ (trofinetide) for the treatment of Rett syndrome in adult and pediatric patients two years of age and older under the Priority Review process. The Notice of Compliance authorization of DAYBUE makes it the first and only drug approved in Canada for the treatment of Rett syndrome. Rett syndrome is a rare, complex, neurodevelopmental disorder affe.

Acadia Pharmaceuticals Announces Health Canada Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome

Acadia (ACAD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why Acadia (ACAD) Could Beat Earnings Estimates Again

Bio-Techne

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Acadia Pharmaceuticals (ACAD) and Techne (TECH). But which of these two stocks is more attractive to value investors?

ACAD or TECH: Which Is the Better Value Stock Right Now?

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on October 3, 2024, the Compensation Committee of Acadia's Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 111,631 shares of common stock and 30,484 restricted stock units (“RSUs”) to thirteen new employees under Acadia's 2024 Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees'.

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Catherine Owen Adams has succeeded Steve Davis as Chief Executive Officer (CEO) and joined the Acadia Board of Directors. “We are excited to welcome Catherine Owen Adams as the new CEO of Acadia,” said Stephen Biggar, M.D., Ph.D., Chair of the Board of Directors. “Catherine is a proven global leader with a distinguished record of accomplishment of driving growth and innovation in the pharmaceutical indus.

Catherine Owen Adams Succeeds Steve Davis as CEO of Acadia Pharmaceuticals

TOKYO--(BUSINESS WIRE)-- #DrugDiscovery--Axcelead Drug Discovery Partners Enters into Master Service Agreement for Drug Discovery Projects with Acadia Pharmaceuticals.

Axcelead Drug Discovery Partners Enters into Master Service Agreement for Drug Discovery Projects with Acadia Pharmaceuticals

Acadia (ACAD) reported earnings 30 days ago. What's next for the stock?

Acadia (ACAD) Up 10% Since Last Earnings Report: Can It Continue?

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at two upcoming investor conferences: Morgan Stanley 22nd Annual Global Healthcare Conference Fireside Chat: Wednesday, September 4, 2024 at 4:50 p.m. Eastern Time in New York, NY Baird 2024 Global Healthcare Conference Fireside Chat: Wednesday, September 11, 2024 at 9:40 a.m. Eastern Time in New York, NY Live webcasts of each fireside chat will be accessible on the company's website,.

Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences

Shares of Acadia trended lower this year due to Daybue's poor quarterly sales performance, and also due to Nuplazid's failure in the phase 3 trial in schizophrenia patients. The full-year guidance on Daybue was reduced as Acadia is finding fewer new patients, not because of higher patient churn. With most of the headwinds in the rearview mirror, I expect better performance of Daybue going forward.

Acadia Pharmaceuticals: Nuplazid Performs In Q2 While Daybue Disappoints Again

SAN DIEGO--(BUSINESS WIRE)--Ryan Reynolds, a world-renowned actor/entrepreneur and Parkinson's disease advocate, with Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the launch of a multi-faceted disease education campaign, More to Parkinson's®, to raise awareness among caregivers, patients and their care providers about a common, yet under-recognized aspect of Parkinson's disease – Parkinson's-related hallucinations and delusions. Notably, around half of the people living with Parki.

Ryan Reynolds Announces More to Parkinson's® Campaign

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at the Canaccord Genuity 44th Annual Growth Conference on Wednesday, August 14, 2024 at 10:00 a.m. Eastern Time. A live webcast of Acadia's fireside chat will be accessible on the company's website, Acadia.com, under the investors section and an archived recording will be available on the website for approximately one month following the presentation. About Acadia P.

Acadia Pharmaceuticals to Participate in the Canaccord Genuity 44th Annual Growth Conference

Acadia Pharmaceuticals led a biotech stock sell-off Wednesday after revenue from its Rett syndrome treatment missed expectations.

Biotech Stocks: Why Acadia Pharma And Others Are Feeling 'Growing Pains'

Acadia (ACAD) reports encouraging second-quarter results as both earnings and revenues beat estimates, driven by higher Nuplazid and Daybue sales.

Acadia (ACAD) Q2 Earnings Beat, Product Sales Drive Revenues

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD ) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Al Kildani - Senior Vice President, Investor Relations and Corporate Communications Steve Davis - President and Chief Executive Officer Brendan Teehan - Chief Operating Officer, Head of Commercial Kimberly Manhard - Senior Vice President, Global Strategic Planning and Execution Mark Schneyer - Chief Financial Officer Parag Meswani - Senior Vice President, Trofinetide Elizabeth Thompson - Executive Vice President, Head of Research and Development Conference Call Participants Ritu Baral - TD Cowen Charles Duncan - Cantor Anish Nikhanj - RBC Capital Markets Joel Beatty - Baird Marc Goodman - Leerink Jeff Hung - Morgan Stanley Keith Tapper - BMO Capital Markets David Hoang - Citigroup Eddie Hickman - Guggenheim Tessa Romero - JPMorgan Operator Good day ladies and gentlemen, and thank you for standing by. Welcome to the ACADIA Pharmaceuticals Second Quarter 2024 Financial Results Conference Call.

ACADIA Pharmaceuticals Inc. (ACAD) Q2 2024 Earnings Call Transcript

Acadia Pharmaceuticals (ACAD) came out with quarterly earnings of $0.20 per share, beating the Zacks Consensus Estimate of $0.16 per share. This compares to earnings of $0.01 per share a year ago.

Acadia Pharmaceuticals (ACAD) Beats Q2 Earnings and Revenue Estimates

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the second quarter ended June 30, 2024. “In the second quarter of 2024, Acadia delivered $242.0 million in net product sales, highlighted by 11% year-over-year growth in NUPLAZID net sales and 11% sequential growth in DAYBUE net sales,” said Steve Davis, Chief Executive Officer. “Additionally, we are advancing enrollment in our Phase 3 trial in Prader-Willi syndrome and our Phase 2 /.

Acadia Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operating Overview

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report second quarter financial results on Tuesday, August 6, 2024, after the close of the U.S. financial markets. Acadia's management team will also host a conference call and webcast on August 6, 2024, at 4:30 p.m. Eastern Time to discuss financial results and operations. The conference call will be available on Acadia's website, Acadia.com under the investors section and will be archived there.

Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 6, 2024

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the journal Med published results from two open-label extension studies, LILAC-1™ and LILAC-2™, which showed that patients treated with DAYBUE™ who completed these studies experienced improvement in Rett symptoms as measured by the Rett Syndrome Behaviour Questionnaire (RSBQ). LILAC-1 was a 40-week, open-label extension study of the 12-week Phase 3 LAVENDER™ trial, evaluating the long-term safety and eff.

Clinical Data from Open-Label Extension LILAC-1™ and LILAC-2™ Studies Evaluating Long-Term Safety and Efficacy of DAYBUE™ (trofinetide) in Patients with Rett Syndrome Published in Med

Acadia Pharmaceuticals  ACAD is a commercial-stage company focused on developing innovative medicines to address unmet medical needs in central nervous system (CNS) disorders and rare diseases. ACAD's commercial portfolio comprises two marketed drugs — Nuplazid (pimavanserin) and Daybue (trofinetide).

HLN vs. LMAT: Which Stock Should Value Investors Buy Now?

Acadia (ACAD) is witnessing robust growth in revenues, driven by Nuplazid and Daybue sales. However, pipeline setbacks, along with stiff competition and dependency on Nuplazid sales, remain a woe.

Acadia's (ACAD) Nuplazid Drives Growth, Pipeline Setbacks a Woe

Acadia Pharmaceuticals, Inc. shares recently hit their lowest level since Daybue approval due to Nuplazid Phase 3 trial failure for schizophrenia. Despite setbacks, Acadia has strong financials with $470.5 million in cash and investments, and is trading at two times FY24 revenue net of cash. An updated analysis around Acadia Pharmaceuticals follows in the paragraphs below.

Acadia Pharmaceuticals: Back In The Buy Zone

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals, Inc. (Nasdaq: ACAD) today announced that interim data from the open-label real-world LOTUS™ study will be presented at the 2024 International Rett Syndrome Foundation (IRSF) Annual Scientific Meeting, being held this week in Westminster, Colorado. LOTUS is an ongoing, caregiver-reported study evaluating the efficacy and tolerability outcomes in patients with Rett syndrome treated with DAYBUE™ (trofinetide). “These interim data from the LOTUS s.

Acadia Pharmaceuticals Presents DAYBUE™ (trofinetide) Real-World Evidence and Additional Data in Rett Syndrome at the 2024 International Rett Syndrome Foundation (IRSF) Annual Scientific Meeting

Allego NV

BERKELEY, Calif.--(BUSINESS WIRE)--Millie, a modern maternity clinic, today revealed promising maternal health outcomes from the first cohort of more than 150 births from its hybrid model that combines midwifery-led care, doulas, and OB-GYN support with technology to provide more complete, proactive, and right-sized care. Millie's 360-degree approach has shown the potential to improve key outcomes while also demonstrating a model for addressing national OB-GYN shortages. Health Outcomes In comp.

News for ACADIA Pharma Stock (ACAD)